Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alere's Triage tests facing potential recall after FDA warning

This article was originally published in Clinica

Executive Summary

Alere's Triage cardiology and toxicology tests could be recalled, after the US FDA sent the company a subpoena relating to quality control testing and performance of the diagnostics. Although the company did not put a figure on the financial impact of a potential recall, Canaccord Genuity analyst Jeffrey Frelick noted that the FDA appears to be focused on the firm's Triage multi-marker cardiology tests, which contribute around $20m of revenues per quarter.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT098899

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel